Recent advances in CD5+ diffuse large B-cell lymphoma
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05974-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2024. Verfasst von Ningning Yue und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, CD5 Antigens, Antineoplastic Combined Chemotherapy Protocols, Doxorubicin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Scientific Research Project of Gansu Province, The "CuiYing postgraduate tutor" training program of Lanzhou University Second Hospital.
Abstract (Originalsprache)
Diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin's lymphoma (NHL), is substantially heterogeneous. Approximately 5-10% of DLBCLs express CD5, which makes CD5+ DLBCL a rare subgroup. Different studies have shown that CD5+ DLBCL patients are often older and female and have higher lactate dehydrogenase levels, an Eastern Cooperative Oncology Group (ECOG) performance status > 1, and higher International Prognostic Index (IPI) scores. Moreover, patients often have advanced stage disease with a high incidence of central nervous system (CNS) relapse and bone marrow involvement. CD5+ DLBCL cells are more likely to express MYC, BCL-2, and MUM-1, less likely to express CD10, and most belong to the activated B-cell-like (ABC) subtype. The potential mechanisms underlying the poor prognosis of CD5+ DLBCL patients may be related to CD5-mediated B-cell receptor (BCR)-dependent and -independent pathways. The efficacy of the traditional rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen is unsatisfactory in CD5+ DLBCL patients. Despite supporting evidence from retrospective studies, it is currently unclear whether dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) can improve outcomes in this population. Several new drugs, such as Bruton tyrosine kinase inhibitors (BTKi), BCL-2 inhibitors, and CXCR4 antagonists, as well as immunotherapy, may help to improve the prognosis of CD5+ DLBCL patients, but additional clinical explorations are needed to determine the optimal therapeutic strategy for this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China.
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu, 730030, China. wuchy0909@163.com.
Förderung
- National Natural Science Foundation of China
- Scientific Research Project of Gansu Province
- The "CuiYing postgraduate tutor" training program of Lanzhou University Second Hospital
- The “CuiYing postgraduate tutor” training program of Lanzhou University Second Hospital
Zitieren
APA
Yue, N., Jin, Q., Li, C., Zhang, L., Cao, J., & Wu, C. (2024). Recent advances in CD5+ diffuse large B-cell lymphoma. Annals of Hematology. https://doi.org/10.1007/s00277-024-05974-8
Vancouver
Yue N, Jin Q, Li C, Zhang L, Cao J, Wu C. Recent advances in CD5+ diffuse large B-cell lymphoma. Annals of Hematology. 2024. doi:10.1007/s00277-024-05974-8
BibTeX
@article{Yue2024,
author = {Yue, Ningning and Jin, Qiqi and Li, Cuicui and Zhang, Litian and Cao, Jiajia and Wu, Chongyang},
title = {Recent advances in CD5+ diffuse large B-cell lymphoma},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05974-8}
}
EUVIMED